Tenax Therapeutics, INC. (TENX) — SEC Filings

Q: What are the key financial highlights for Tenax Therapeutics, INC.?

Key financial highlights for Tenax Therapeutics, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Tenax Therapeutics, INC.?

Key executives at Tenax Therapeutics, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Tenax Therapeutics, INC. stock?

Risk factors for Tenax Therapeutics, INC. (TENX) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Tenax Therapeutics, INC.?

Forward-looking statements and predictions from Tenax Therapeutics, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Tenax Therapeutics, INC.. Recent EFFECT filing on Apr 2, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Tenax Therapeutics, INC. on SEC EDGAR

Overview

Tenax Therapeutics, INC. (TENX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-3 filed on Mar 24, 2026: TENAX THERAPEUTICS, INC. filed an S-3 registration statement on March 24, 2026, allowing them to potentially sell new securities like stocks or bonds in the future. This filing, under SEC Accession No. 0001654954-26-002661, doesn't mean they are selling anything right now, but it gives them the flex

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant filing sentiment for Tenax Therapeutics, INC. is neutral.

Filing Type Overview

Tenax Therapeutics, INC. (TENX) has filed 1 EFFECT, 1 S-3, 20 8-K, 6 10-Q, 3 DEF 14A, 1 10-K, 4 SC 13G/A, 11 SC 13G, 1 DEFA14A, 2 S-1/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

EFFECT Filing — EFFECT · Apr 2, 2026
TENAX THERAPEUTICS Files S-3 Shelf Registration — S-3 · Mar 24, 2026
TENAX THERAPEUTICS, INC. filed an S-3 registration statement on March 24, 2026, allowing them to potentially sell new securities like stocks or bonds in the fut
Tenax Therapeutics Files 8-K Report — 8-K · Dec 17, 2025 Risk: low
On December 17, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
8-K Filing — 8-K · Nov 12, 2025
Tenax Therapeutics' Losses Mount Amid R&D Surge, Cash Position Strong — 10-Q · Nov 12, 2025 Risk: high
TENAX THERAPEUTICS, INC. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $37.059 million, a substantial rise
Tenax Therapeutics Files 8-K — 8-K · Sep 16, 2025 Risk: low
On September 16, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with
Tenax Therapeutics Files 8-K for Material Agreement — 8-K · Sep 9, 2025 Risk: medium
On September 3, 2025, Tenax Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Oxygen Biotherapeutics, Inc., filed
Tenax Therapeutics Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
On August 13, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
Tenax Therapeutics' Burn Rate Soars Amid R&D Push, Cash Reserves Up — 10-Q · Aug 13, 2025 Risk: high
TENAX THERAPEUTICS, INC. reported a significant increase in net loss for the six months ended June 30, 2025, reaching $21.255 million, up from $7.374 million in
Tenax Therapeutics Files 8-K with Corporate Updates — 8-K · Jun 17, 2025 Risk: low
On June 11, 2025, Tenax Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, submission of matters to a vote
Tenax Therapeutics Files Q1 2025 10-Q — 10-Q · May 14, 2025 Risk: medium
Tenax Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business op
Tenax Therapeutics Executive Compensation Details Revealed — DEF 14A · Apr 25, 2025 Risk: medium
Tenax Therapeutics, Inc. filed its DEF 14A on April 25, 2025, detailing executive compensation and stock awards for the fiscal years ending December 31, 2022, 2
Tenax Therapeutics Files 2024 10-K — 10-K · Mar 25, 2025 Risk: medium
Tenax Therapeutics, Inc. filed its 2024 10-K on March 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Oxygen Bio
Tenax Therapeutics Files 8-K: Material Agreement, Equity Sales — 8-K · Mar 6, 2025 Risk: medium
On March 4, 2025, Tenax Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
Tenax Therapeutics Announces Director and Officer Changes — 8-K · Dec 4, 2024 Risk: medium
On December 2, 2024, Tenax Therapeutics, Inc. filed an 8-K report detailing the election of new directors and the appointment of new officers. The filing also i
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
SC 13G Filing — SC 13G · Nov 14, 2024
Tenax Therapeutics Q3 2024 Update — 10-Q · Nov 13, 2024 Risk: high
Tenax Therapeutics, Inc. filed a 10-Q for the period ending September 30, 2024. The company reported total assets of $4.8 million and total liabilities of $5.2
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
SC 13G Filing — SC 13G · Nov 12, 2024
Tenax Therapeutics Announces Director Changes and Stockholder Meeting — 8-K · Oct 30, 2024 Risk: medium
On October 25, 2024, Tenax Therapeutics, Inc. filed an 8-K report detailing the departure of Director Dr. David J. Mazzo and the election of new Director Dr. Da
Tenax Therapeutics Files Proxy Statement for Annual Meeting — DEF 14A · Sep 27, 2024 Risk: low
Tenax Therapeutics, Inc. filed its definitive proxy statement on September 27, 2024, for its annual meeting of stockholders. The filing outlines the proposals t
SC 13G Filing — SC 13G · Sep 10, 2024
SC 13G Filing — SC 13G · Aug 19, 2024
SC 13G Filing — SC 13G · Aug 19, 2024
SC 13G Filing — SC 13G · Aug 15, 2024
SC 13G Filing — SC 13G · Aug 14, 2024
SC 13G Filing — SC 13G · Aug 14, 2024
Tenax Therapeutics Reports Q2 Loss, Announces Private Placement — 10-Q · Aug 13, 2024 Risk: medium
Tenax Therapeutics, Inc. filed its Q2 2024 10-Q report on August 13, 2024. The company reported total assets of $5.18 million and total liabilities of $0.21 mil
Tenax Therapeutics Files 8-K Report — 8-K · Aug 12, 2024 Risk: low
On August 12, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
Tenax Therapeutics Files 8-K for Financial Statements — 8-K · Aug 6, 2024 Risk: low
On August 6, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material even
Tenax Therapeutics Appoints New Officers, Elects Directors — 8-K · Jun 13, 2024 Risk: medium
On June 7, 2024, Tenax Therapeutics, Inc. announced the appointment of Dr. Christopher P. Bartus as Chief Medical Officer and Dr. Jonathan P. Stine as Chief Sci
Tenax Therapeutics Files Proxy Materials — DEFA14A · May 24, 2024 Risk: low
Tenax Therapeutics, Inc. filed a Definitive Additional Materials proxy statement on May 24, 2024. This filing relates to the company's solicitation of proxies f
Tenax Therapeutics Q1 2024: Assets and Liabilities — 10-Q · May 14, 2024 Risk: medium
Tenax Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2024. The company reported total assets of $4.8 million and total liabilities of $0.9 mill
Tenax Therapeutics, Inc. Announces Annual Meeting of Stockholders on June 7, 2024 — DEF 14A · Apr 26, 2024 Risk: low
TENAX THERAPEUTICS, INC. (TENX) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The Annual Meeting of Stockholders for Tenax Therapeutics, Inc
Tenax Therapeutics Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
On March 28, 2024, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations, with
Tenax Therapeutics Files 8-K on Feb 22nd Event — 8-K · Feb 23, 2024 Risk: medium
Tenax Therapeutics, Inc. (TENAX) filed an 8-K on February 23, 2024, reporting an event that occurred on February 22, 2024. The filing indicates a current report
Tenax Therapeutics Enters Material Definitive Agreement — 8-K · Feb 20, 2024 Risk: medium
Tenax Therapeutics, Inc. entered into a Material Definitive Agreement on February 19, 2024. This 8-K filing, dated February 20, 2024, reports on this agreement,
SC 13G Filing — SC 13G · Feb 20, 2024
SC 13G Filing — SC 13G · Feb 16, 2024
SC 13G Filing — SC 13G · Feb 15, 2024
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
TENAX THERAPEUTICS FILES 8-K ON MATERIAL AGREEMENT; DETAILS UNDISCLOSED — 8-K · Feb 12, 2024 Risk: medium
On February 8, 2024, Tenax Therapeutics, Inc. (TENX) filed an 8-K to report an "Entry into a Material Definitive Agreement" and "Other Events." While the filing
TENAX THERAPEUTICS FILES 8-K: ROUTINE 'OTHER EVENTS' DISCLOSURE — 8-K · Feb 8, 2024 Risk: low
Tenax Therapeutics, Inc. filed an 8-K on February 8, 2024, reporting an event that occurred on February 7, 2024. This filing is a routine update to the SEC, ind
Tenax Therapeutics Files 8-K on Feb 6, Confirms Nasdaq Listing — 8-K · Feb 6, 2024
Tenax Therapeutics, Inc. filed an 8-K on February 6, 2024, to report an "Other Event" and provide "Financial Statements and Exhibits." This filing indicates tha
Tenax Therapeutics Files S-1/A Amendment for XBRL Exhibits — S-1/A · Feb 2, 2024 Risk: low
TENAX THERAPEUTICS, INC. (TENX) filed a Amended IPO Registration (S-1/A) with the SEC on February 2, 2024. Tenax Therapeutics, Inc. filed an S-1/A amendment on
Tenax Therapeutics, Inc. Files S-1/A Amendment — S-1/A · Feb 1, 2024 Risk: low
TENAX THERAPEUTICS, INC. (TENX) filed a Amended IPO Registration (S-1/A) with the SEC on February 1, 2024. Tenax Therapeutics, Inc. filed an S-1/A amendment on
Tenax Therapeutics Confirms Nasdaq Listing for Common Stock — 8-K · Jan 19, 2024
Tenax Therapeutics, Inc. filed an 8-K on January 18, 2024, to update its registration information, specifically confirming its Common Stock, $0.0001 par value p
TENAX THERAPEUTICS FACES NASDAQ DELISTING THREAT — 8-K · Jan 12, 2024
Tenax Therapeutics, Inc. announced on January 9, 2024, that it received a notice from the Nasdaq Stock Market indicating its failure to meet continued listing s

Risk Profile

Risk Assessment: Of TENX's 29 recent filings, 3 were flagged as high-risk, 13 as medium-risk, and 13 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Tenax Therapeutics, INC.'s most recent 10-Q filing (Nov 12, 2025):

Revenue: N/A
Net Income: -$37.059M
EPS: -$0.96
Debt-to-Equity: 0.07
Cash Position: $99.369M
Operating Margin: N/A
Total Assets: $102.810M
Total Debt: $6.599M

Key Executives

Dr. David J. Mazzo
Dr. David L. Schlessinger
Chief Medical Officer
Dr. Christopher P. Bartus
Dr. Jonathan P. Stine
Christopher T. Giordano

Industry Context

Tenax Therapeutics operates in the biopharmaceutical industry, focusing on developing therapies for cardiovascular diseases. This sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success often hinges on securing intellectual property, navigating clinical trials, and obtaining regulatory approvals, with companies frequently relying on external financing to fund these capital-intensive endeavors.

Top Tags

financials (7) · filing (5) · material-agreement (4) · 10-Q (4) · 8-k (3) · pharmaceuticals (3) · 8-K (3) · corporate-governance (3) · regulatory-filing (3) · sec-filing (2)

Key Numbers

Net Loss: $37.059M — for the nine months ended September 30, 2025, up from $11.335M in 2024
Cash and Cash Equivalents: $99.369M — as of September 30, 2025, up from $94.851M at December 31, 2024
Research and Development Expenses: $22.132M — for the nine months ended September 30, 2025, up from $8.115M in 2024
General and Administrative Expenses: $17.804M — for the nine months ended September 30, 2025, up from $4.084M in 2024
Accumulated Deficit: $351.914M — as of September 30, 2025, up from $314.855M at December 31, 2024
Common Stock Shares Outstanding: 5,907,233 — as of September 30, 2025, up from 3,420,906 at December 31, 2024
Contingent Commercialization Milestone Payments: $45.0M — due to Orion Corporation upon achievement of certain cumulative worldwide sales
Milestone Payment: $10.0M — due to Orion upon FDA approval of a levosimendan-based product
SEC File Number: 001-34600 — Identifies the company's filing with the SEC.
IRS Employer Identification No.: 26-2593535 — Company's tax identification number.
R&D Expenses: $11.804M — More than doubled from $5.003M in 2024, reflecting increased drug development.
G&A Expenses: $11.326M — Significantly rose from $2.577M in 2024, contributing to higher operating costs.
Cash & Cash Equivalents: $105.462M — Increased from $94.851M at Dec 31, 2024, bolstered by financing activities.
Net Proceeds from Financing: $23.2M — Raised in March 2025 private placement, providing crucial liquidity.
Orion Regulatory Milestones: $15.0M — Potential future payments upon levosimendan regulatory approvals.

Forward-Looking Statements

{"claim":"Tenax Therapeutics will release further details about the material definitive agreement in a subsequent filing or press release.","entity":"Tenax Therapeutics, Inc.","targetDate":"2024-03-31","confidence":"high"}
{"claim":"The stock price of TENX will experience volatility until more information about the agreement is disclosed.","entity":"TENX","targetDate":"2024-03-31","confidence":"medium"}

Frequently Asked Questions

What are the latest SEC filings for Tenax Therapeutics, INC. (TENX)?

Tenax Therapeutics, INC. has 50 recent SEC filings from Jan 2024 to Apr 2026, including 20 8-K, 11 SC 13G, 6 10-Q. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of TENX filings?

Across 50 filings, the sentiment breakdown is: 2 bearish, 46 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Tenax Therapeutics, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Tenax Therapeutics, INC. (TENX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Tenax Therapeutics, INC.?

Key financial highlights from Tenax Therapeutics, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for TENX?

The investment thesis for TENX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Tenax Therapeutics, INC.?

Key executives identified across Tenax Therapeutics, INC.'s filings include Dr. David J. Mazzo, Dr. David L. Schlessinger, Chief Medical Officer, Dr. Christopher P. Bartus, Dr. Jonathan P. Stine and 1 others.

What are the main risk factors for Tenax Therapeutics, INC. stock?

Of TENX's 29 assessed filings, 3 were flagged high-risk, 13 medium-risk, and 13 low-risk.

What are recent predictions and forward guidance from Tenax Therapeutics, INC.?

Recent forward-looking statements from Tenax Therapeutics, INC. include guidance on {"claim":"Tenax Therapeutics will release further details about the material definitive agreement in a subsequent filing and 1 other predictions.